The power of our transpacific partnerships lies at the heart of our investment and company building strategy. We leverage an extensive global network as well as an &#8220;on-the-ground&#8221;, local presence in both Japan and the United States. This enables us to access differentiated sourcing and early-stage investment opportunities for the creation and development of bespoke new biotech companies on both sides of the Pacific. Through this approach, the team gains insights and perspectives that enable it to maximize therapeutic impact for patients around the world, while generating attractive risk-adjusted returns for investors.

Eiji Tanaka

Managing Executive Officer of Mitsubishi Tanabe Pharma Corporation

Mineralys Therapeutics is a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension – the leading cause of heart and kidney disease. Mineralys is driven to break the “trial and failure” approach and bring a personalized, targeted approach to the management of hypertension. Through its expertise and focus on the patient, Mineralys aims to change the way hypertension is diagnosed, managed and treated.

A Targeted Approach for the Control of Hypertension

Mineralys - Catalys Pacific

Casey Logan

CBO at Travere Therapeutics, Inc.

Renalys Pharma is a private, late-stage clinical biopharmaceutical company committed to the development of innovative therapeutics that address unmet needs in the management of renal disease. It was co-founded by Catalys Pacific and SR One. Renalys’ current efforts are centered on bringing sparsentan, an investigational dual-acting treatment developed by Travere Therapeutics, to patients in Japan as well as other Asian countries more broadly.

Catalyst to access novel therapies for Asian patients with renal disease

Renalys - Catalys Pacific

Takashi Shibano

Senior Vice President of EA Pharma

Pathalys Pharma, Inc. (“Pathalys”) is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end-stage kidney disease (“ESKD”). Pathalys’ initial asset is upacicalcet (Pathalys code: PLS240), a novel calcimimetic with the potential to improve the treatment of secondary hyperparathyroidism (“SHPT”), approved in Japan under the brand name UPASITA®. Beyond PLS240, Pathalys continues to identify other high priority needs and potential solutions for patients with chronic kidney disease (“CKD”) and ESKD.

A New Path for Patients with Chronic Kidney Disease

Pathalys - Catalys Pacific

<span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;Improving patient lives worldwide by driving impact and innovation in healthcare and contributing to advancements in life sciences.&quot;}" data-sheets-userformat="{&quot;2&quot;:14783,&quot;3&quot;:{&quot;1&quot;:0,&quot;3&quot;:1},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16703948},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;10&quot;:1,&quot;11&quot;:4,&quot;14&quot;:{&quot;1&quot;:2,&quot;2&quot;:0},&quot;15&quot;:&quot;Arial&quot;,&quot;16&quot;:10}">Improving patient lives worldwide by driving impact and innovation in healthcare and contributing to advancements in life sciences.

Starting with gratitude for the opportunity to create meaningful healthcare innovations alongside our partners.

Success in entrepreneurship arises from inspiration, yet only is realized through its execution with perseverance, persistence and creativity.

Knowing that true innovation requires an agility and resilience to embrace change, confront challenges, learn from failures, and to pivot accordingly.

We embrace a compass of ethics to better society and science, choosing not to waver in the face of moral crisis.

Framed by successful sails at times, turbulent tides at others.

Crafted venture backed companies designed to excel in healthcare innovation, no matter where their journey takes them.

Our ultimate destination is to better patients’ lives.

Improving patient lives worldwide by driving impact and innovation in healthcare and contributing to advancements in life sciences.

Charter - Catalys Pacific

Catalys Pacific

Catalys Pacific maximizes its profound global network and robust local presence in Japan to propel its mission of improving patient lives. It is an honor to be a part of that mission.”

Transforming Life Sciences Innovation By Creating And Investing In Global Companies

Home

ART5803 is a precision therapeutic candidate designed to directly inhibit the pathogenic effects of anti-NMDA receptor autoantibodies Fast Track designation enables a more expedited regulatory review of ART5803, which has also received U.S. FDA Orphan Drug and Rare Pediatric Disease designations, as well as Orphan Drug designation from South Korea’s MFDS. LA JOLLA, Calif., July [&hellip;]

Arialys Therapeutics Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of Anti-NMDA Receptor Encephalitis - Catalys Pacific

Arialys Therapeutics Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of Anti-NMDA Receptor Encephalitis

CHART THE UNCHARTED

New Current

Arialys Therapeutics Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of Anti-NMDA Receptor Encephalitis

Featured Creations

Mineralys

Renalys

Pathalys

Catalyzing Transpacific Partnership